Shots:

• ABL to receive $75M up front & is eligible to receive ~$985M upon achievement of predefined development, regulatory & commercialization milestones including $45M in near-term milestones along with royalties on net sales
• Sanofi to get exclusive development and commercialization rights globally for ABL301 & will lead the clinical development, regulatory approval & commercialization of ABL301. ABL will be responsible for the preclinical development & P-I clinical trial of ABL301
• The collaboration will use ABL's Grabody-B platform technology to advance ABL301 which transmit the anti-alpha-synuclein Ab across the BBB to boost therapeutic efficacy against Parkinson's disease

Ref: PR Newswire | Image: Medcity News